New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
09:01 EDTDNDNDendreon's Provenge still facing headwinds, says RW Baird
Baird's Provenge checks continue to show slow acceptance, slower than expected pace for expense savings, and concerns surrounding competition. The firm recommends staying on the sidelines in Dendreon shares and maintatins its Neutral rating and $6 price target.
News For DNDN From The Last 14 Days
Check below for free stories on DNDN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 11, 2014
07:01 EDTDNDNDendreon: Immune responses enhanced when Provenge given after ADT
Dendreon Corporation announced the presentation of preliminary data from a long-term analysis of the Phase II STAND study demonstrating that tumor-specific T-cell responses appear to be enhanced and sustained when PROVENGE is given after androgen deprivation therapy in patients with biochemically-recurrent prostate cancer at high risk for metastases. These data will be presented at the 29th Annual European Association of Urology Congress taking place from April 11-15, 2014 in Stockholm, Sweden.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use